European Medicines Agency Approves Relistor? The First-In-Class Treatment Of Opioid-Induced Constipation (Oic) In Advanced-Illness Patients
Jul 4th 2008Drug InformationGastroIntestinal / Gastroentorology
Wyeth Pharmaceuticals, 3rd July, announced that it has received EMEA marketing approval for Relistor? (methylnaltrexone bromide) subcutaneous injection. This first-in-class treatment is indicated for opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to the usual laxative therapy has not been sufficient.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
